Cholesterol Lowering Drugs Market
Cholesterol Lowering Drugs Market Size, Share & Trends Analysis by Drug Class (Statins, PCSK9 Inhibitors, Bile Acid Sequestrants, Fibrates, Cholesterol Absorption Inhibitors, Combination Therapy, and Others), by Indication (Hypercholesterolemia, Cardiovascular Risk Reduction / Atherosclerosis, Hypertriglyceridemia), by Route of Administration (Oral, and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Forecast Period (2026-2035)
Industry Overview
Cholesterol lowering drugs market was valued at $23.2 billion in 2025 and is projected to reach $35.8 billion by 2035, growing at a CAGR of 4.5% during the forecast period (2026-2035). The market is growing due to the rising prevalence of cardiovascular diseases and associated hypercholesterolemia, which has increased the demand for effective lipid-lowering therapies across all age groups. This trend is further supported by the expanding adoption of advanced treatment options, such as PCSK9 inhibitors and combination therapies, which offer targeted cholesterol management and improved patient outcomes. Increasing awareness among healthcare professionals and patients regarding the long-term benefits of cholesterol control has also contributed to higher prescription rates. Additionally, the growing availability of these drugs through diverse distribution channels, including hospital pharmacies, retail outlets, and online platforms, has enhanced accessibility and convenience, facilitating broader market penetration.
Market Dynamics
Rising Adoption of Innovative Biologic Therapies
The market is witnessing increasing adoption of biologic therapies, particularly PCSK9 inhibitors and siRNA-based treatments, which provide targeted and effective LDL cholesterol reduction for high-risk patients. These therapies are driving growth by addressing unmet needs in patients who are intolerant to statins or require additional lipid-lowering support. Clinical validation of these biologics has strengthened physician confidence, leading to broader prescription rates. The convenience of injectable dosing and favorable efficacy profiles further support patient adherence and market uptake. Consequently, the integration of these innovative therapies is reshaping treatment paradigms and expanding the overall cholesterol-lowering drug market.
Expansion of Generic Statins and Cost-Effective Options
The market is also supported by the increasing availability of generic statins and cost-effective combination therapies, which enhance accessibility for a larger patient population. Reduced treatment costs encourage long-term therapy adherence, particularly in emerging markets where affordability remains a key consideration. Regulatory approvals and patent expirations have facilitated the entry of multiple generic manufacturers, increasing competition and broadening distribution. This trend enables healthcare systems to manage hypercholesterolemia efficiently while maintaining high treatment coverage. As a result, the growing penetration of affordable alternatives is a significant contributor to market expansion.
Market Segmentation
- Based on the drug class, the market is segmented into statins, PCSK9 inhibitors, bile acid sequestrants, fibrates, cholesterol absorption inhibitors, combination therapy, and others.
- Based on the indication, the market is segmented into hypercholesterolemia, cardiovascular risk reduction/atherosclerosis, and hypertriglyceridemia.
- Based on the route of administration, the market is segmented into oral, and injectable.
- Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
Statins: Leading Oral Therapy Driving Market Growth
Statins remain the largest and most widely prescribed class within the cholesterol-lowering drugs market, primarily due to their proven efficacy in reducing LDL cholesterol and preventing cardiovascular events. Growth in this sub-segment is driven by the high prevalence of hypercholesterolemia globally, coupled with extensive clinical adoption across adult and geriatric populations. The availability of generic statins has further expanded patient access, particularly in cost-sensitive markets, supporting consistent prescription volumes. Additionally, combination therapies incorporating statins enhance treatment outcomes for high-risk patients, reinforcing market demand.
PCSK9 Inhibitors: Emerging Injectable Therapies Expanding Market Share
PCSK9 inhibitors are a rapidly growing injectable sub-segment, offering targeted LDL cholesterol reduction for patients inadequately controlled by statins or intolerant to conventional therapy. Their growth is underpinned by increasing physician preference for biologics that deliver superior efficacy and long-term cardiovascular risk management. Recent approvals of siRNA-based variants, such as inclisiran, have strengthened patient adherence through less frequent dosing schedules. Adoption is further supported by healthcare programs and reimbursement policies in developed markets, enhancing accessibility. As a result, PCSK9 inhibitors are capturing an expanding share of the global cholesterol-lowering drugs market.
Regional Outlook
The global Cholesterol Lowering Drugs market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
Leading Region: North America Dominates the Cholesterol-Lowering Drugs Market
North America, led by the US, holds the largest share in the global cholesterol-lowering drugs market, driven by the high prevalence of hypercholesterolemia and widespread adoption of statins and PCSK9 inhibitors. Strong healthcare infrastructure, advanced clinical awareness, and comprehensive reimbursement policies support consistent prescription rates across adults and geriatric patients. Key industry participants such as Pfizer, Amgen, and Novartis maintain significant market presence through both branded and biologic therapies. The region also benefits from early adoption of innovative treatments like inclisiran, enhancing patient adherence and long-term cardiovascular management. These factors collectively reinforce North America’s position as the dominant market for cholesterol-lowering therapies.
Fastest Growing Region: Asia-Pacific Experiences Rapid Market Expansion
Asia-Pacific is emerging as the fastest-growing region in the cholesterol-lowering drugs market, fueled by rising cardiovascular disease prevalence, increasing urbanization, and expanding healthcare access. Growth is accelerated by rising awareness of hypercholesterolemia and government initiatives promoting preventive cardiovascular care. Countries such as China, India, and Japan are witnessing increased adoption of both statins and novel PCSK9 inhibitors, with companies like Novartis, Pfizer, and Amgen expanding distribution networks. The growing availability of generic therapies also supports affordability and penetration across diverse patient populations. As a result, the Asia-Pacific demonstrates the highest growth momentum within the global market.
Market Players Outlook
The major companies operating in the global cholesterol-lowering drugs market include Amgen Inc., AstraZeneca plc, Novartis AG, Pfizer Inc., Sanofi S.A., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In July 2025, Novartis announced FDA approval of a label update for Leqvio® (inclisiran), allowing its use as monotherapy with diet and exercise to reduce LDL cholesterol in adults with hypercholesterolemia. The FDA requested the update based on strong LDL-C-lowering data for PCSK9-targeting therapies.
- In June 2025, Eli Lilly acquired Verve Therapeutics, a clinical-stage biotech focused on gene editing treatments for atherosclerotic cardiovascular disease (ASCVD). Verve's lead candidate, VERVE-102, is an in vivo gene editing therapy targeting PCSK9 to manage cholesterol and cardiovascular health.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global cholesterol-lowering drugs market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Cholesterol Lowering Drugs Market Sales Analysis – Drug Class | Indication | Route of Administration | Distribution Channel ($ Million)
- Cholesterol Lowering Drugs Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Cholesterol Lowering Drugs Market Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Cholesterol Lowering Drugs Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For Global Cholesterol Lowering Drugs Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Cholesterol Lowering Drugs Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Cholesterol Lowering Drugs Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Cholesterol Lowering Drugs Market Revenue and Share by Manufacturers
- Cholesterol Lowering Drugs Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- Amgen Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- AstraZeneca plc
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Novartis AG
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Pfizer Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Sanofi S.A.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- Amgen Inc.
- Key Company Analysis
- Global Cholesterol Lowering Drugs Market Sales Analysis by Drug Class ($ Million)
- Statins
- PCSK9 Inhibitors
- Bile Acid Sequestrants
- Fibrates
- Cholesterol Absorption Inhibitors
- Combination Therapy
- Others
- Global Cholesterol Lowering Drugs Market Sales Analysis by Indication ($ Million)
- Hypercholesterolemia
- Cardiovascular Risk Reduction / Atherosclerosis
- Hypertriglyceridemia
- Global Cholesterol Lowering Drugs Market Sales Analysis by Route of Administration ($ Million)
- Oral
- Injectable
- Global Cholesterol Lowering Drugs Market Sales Analysis by Distribution Channel ($ Million)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Analysis
- North American Cholesterol Lowering Drugs Market Sales Analysis – Drug Class | Indication | Route of Administration | Distribution Channel | Country ($ Million)
- United States
- Canada
- North American Cholesterol Lowering Drugs Market Sales Analysis – Drug Class | Indication | Route of Administration | Distribution Channel | Country ($ Million)
- European Cholesterol Lowering Drugs Market Sales Analysis – Drug Class | Indication | Route of Administration | Distribution Channel | Country ($ Million)
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Cholesterol Lowering Drugs Market Sales Analysis – Drug Class | Indication | Route of Administration | Distribution Channel | Country ($ Million)
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Cholesterol Lowering Drugs Market Sales Analysis – Drug Class | Indication | Route of Administration | Distribution Channel | Country ($ Million)
- Latin America
- Middle East and Africa
- Company Profiles
- AbbVie Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Amgen Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AstraZeneca plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bayer AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Boehringer Ingelheim GmbH
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Biocon Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bristol?Myers Squibb Company
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Daiichi Sankyo Company, Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Reddy’s Laboratories Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Eli Lilly and Company
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GlaxoSmithKline plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Johnson & Johnson
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Merck & Co., Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Novartis AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Regeneron Pharmaceuticals, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sanofi S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sun Pharmaceutical Industries Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Takeda Pharmaceutical Company Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Viatris
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AbbVie Inc.
1. Global Cholesterol Lowering Drugs Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
2. Global Statins Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global PCSK9 Inhibitors Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Bile Acid Sequestrants Market Research and Analysis by Region, 2025–2035 ($ Million)
5. Global Fibrates Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global Cholesterol Absorption Inhibitors Market Research and Analysis by Region, 2025–2035 ($ Million)
7. Global Combination Therapy Market Research and Analysis by Region, 2025–2035 ($ Million)
8. Global Other Cholesterol Lowering Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
9. Global Cholesterol Lowering Drugs Market Research and Analysis by Indication, 2025–2035 ($ Million)
10. Global Cholesterol Lowering Drugs For Hypercholesterolemia Market Research and Analysis by Region, 2025–2035 ($ Million)
11. Global Cholesterol Lowering Drugs For Cardiovascular Risk Reduction / Atherosclerosis Market Research and Analysis by Region, 2025–2035 ($ Million)
12. Global Cholesterol Lowering Drugs For Hypertriglyceridemia Market Research and Analysis by Region, 2025–2035 ($ Million)
13. Global Cholesterol Lowering Drugs Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
14. Global Cholesterol Lowering Oral Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
15. Global Cholesterol Lowering Injectable Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
16. Global Cholesterol Lowering Drugs Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
17. Global Cholesterol Lowering Drugs by Hospital Pharmacies Market Research and Analysis by Region, 2025–2035 ($ Million)
18. Global Cholesterol Lowering Drugs by Retail Pharmacies Market Research and Analysis by Region, 2025–2035 ($ Million)
19. Global Cholesterol Lowering Drugs by Online Pharmacies Market Research and Analysis by Region, 2025–2035 ($ Million)
20. Global Cholesterol Lowering Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
21. North American Cholesterol Lowering Drugs Market Research and Analysis by Country, 2025–2035 ($ Million)
22. North American Cholesterol Lowering Drugs Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
23. North American Cholesterol Lowering Drugs Market Research and Analysis by Indication, 2025–2035 ($ Million)
24. | Route of Administration
25. North American Cholesterol Lowering Drugs Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
26. European Cholesterol Lowering Drugs Market Research and Analysis by Country, 2025–2035 ($ Million)
27. European Cholesterol Lowering Drugs Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
28. European Cholesterol Lowering Drugs Market Research and Analysis by Indication, 2025–2035 ($ Million)
29. | Route of Administration
30. European Cholesterol Lowering Drugs Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
31. Asia-Pacific Cholesterol Lowering Drugs Market Research and Analysis by Country, 2025–2035 ($ Million)
32. Asia-Pacific Cholesterol Lowering Drugs Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
33. Asia-Pacific Cholesterol Lowering Drugs Market Research and Analysis by Indication, 2025–2035 ($ Million)
34. | Route of Administration
35. Asia-Pacific Cholesterol Lowering Drugs Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
36. Rest of the World Cholesterol Lowering Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
37. Rest of the World Cholesterol Lowering Drugs Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
38. Rest of the World Cholesterol Lowering Drugs Market Research and Analysis by Indication, 2025–2035 ($ Million)
39. | Route of Administration
40. Rest of the World Cholesterol Lowering Drugs Market Research and Analysis by Distribution Channel, 2025–2035 ($ Million)
1. Global Cholesterol Lowering Drugs Market Share by Drug Class, 2025 vs 2035 (%)
2. Global Statins Market Share by Region, 2025 vs 2035 (%)
3. Global PCSK9 Inhibitors Market Share by Region, 2025 vs 2035 (%)
4. Global Bile Acid Sequestrants Market Share by Region, 2025 vs 2035 (%)
5. Global Fibrates Market Share by Region, 2025 vs 2035 (%)
6. Global Cholesterol Absorption Inhibitors Market Share by Region, 2025 vs 2035 (%)
7. Global Combination Therapy Market Share by Region, 2025 vs 2035 (%)
8. Global Other Cholesterol Lowering Drugs Market Share by Region, 2025 vs 2035 (%)
9. Global Cholesterol Lowering Drugs Market Share by Indication, 2025 vs 2035 (%)
10. Global Cholesterol Lowering Drugs For Hypercholesterolemia Market Share by Region, 2025 vs 2035 (%)
11. Global Cholesterol Lowering Drugs For Cardiovascular Risk Reduction / Atherosclerosis Market Share by Region, 2025 vs 2035 (%)
12. Global Cholesterol Lowering Drugs For Hypertriglyceridemia Market Share by Region, 2025 vs 2035 (%)
13. Global Cholesterol Lowering Drugs Market Share by Distribution Channel, 2025 vs 2035 (%)
14. Global Cholesterol Lowering Drugs by Hospital Pharmacies Market Share by Region, 2025 vs 2035 (%)
15. Global Cholesterol Lowering Drugs by Retail Pharmacies Market Share by Region, 2025 vs 2035 (%)
16. Global Cholesterol Lowering Drugs by Online Pharmacies Market Share by Region, 2025 vs 2035 (%)
17. Global Cholesterol Lowering Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
18. US Cholesterol Lowering Drugs Market Size, 2025–2035 ($ Million)
19. Canada Cholesterol Lowering Drugs Market Size, 2025–2035 ($ Million)
20. UK Cholesterol Lowering Drugs Market Size, 2025–2035 ($ Million)
21. France Cholesterol Lowering Drugs Market Size, 2025–2035 ($ Million)
22. Germany Cholesterol Lowering Drugs Market Size, 2025–2035 ($ Million)
23. Italy Cholesterol Lowering Drugs Market Size, 2025–2035 ($ Million)
24. Spain Cholesterol Lowering Drugs Market Size, 2025–2035 ($ Million)
25. Russia Cholesterol Lowering Drugs Market Size, 2025–2035 ($ Million)
26. Rest of Europe Cholesterol Lowering Drugs Market Size, 2025–2035 ($ Million)
27. India Cholesterol Lowering Drugs Market Size, 2025–2035 ($ Million)
28. China Cholesterol Lowering Drugs Market Size, 2025–2035 ($ Million)
29. Japan Cholesterol Lowering Drugs Market Size, 2025–2035 ($ Million)
30. South Korea Cholesterol Lowering Drugs Market Size, 2025–2035 ($ Million)
31. Australia and New Zealand Cholesterol Lowering Drugs Market Size, 2025–2035 ($ Million)
32. ASEAN Economies Cholesterol Lowering Drugs Market Size, 2025–2035 ($ Million)
33. Rest of Asia-Pacific Cholesterol Lowering Drugs Market Size, 2025–2035 ($ Million)
34. Latin America Cholesterol Lowering Drugs Market Size, 2025–2035 ($ Million)
35. Middle East and Africa Cholesterol Lowering Drugs Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of users within the company
